3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
47
Carcinoma, Non-Small-Cell Lung
14
Neoplasm Metastasis
11
Neoplasms
9
Colorectal Neoplasms
8
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Lung Neoplasms
6
Sarcoma
5
Melanoma
4
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Pancreatic Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
TNBC
1
Solid Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
pembrolizumab
9
Pemetrexed
7
Cyclophosphamide
6
Nivolumab
5
Ipilimumab
5
Cisplatin
5
Carboplatin
5
fludarabine
4
Drug Therapy
2
Bevacizumab
2
tremelimumab
1
tocilizumab
1
tazemetostat
1
spartalizumab
1
sotorasib
1
rebastinib
1
poly ICLC
1
pevonedistat
1
osimertinib
1
milademetan
1
fludarabine phosphate
1
epacadostat
1
durvalumab
1
defactinib
1
atezolizumab
1
aldesleukin
1
Vorinostat
1
Thiostrepton
1
Tablets
1
Plicamycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Mesothelioma
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled